Literature DB >> 18832738

Effect of CpG oligonucleotides on vaccine-induced B cell memory.

Debra Tross1, Dennis M Klinman.   

Abstract

Adding synthetic oligodeoxynucleotides containing unmethylated CpG motifs to Anthrax vaccine adsorbed (AVA, the licensed human vaccine) increases the speed and magnitude of the resultant Ab response. Ab titers persist in the protective range for >1 year, significantly longer than in animals vaccinated with AVA alone. Unexpectedly, a majority of mice immunized with CpG-adjuvanted AVA maintained resistance to anthrax infection even after their Ab titers had declined into the subprotective range. The survival of these animals was mediated by the de novo production of protective Abs by high affinity memory B cells re-stimulated immediately after challenge. Thus, a previously unrecognized benefit of CpG oligodeoxynucleotides adjuvants is their ability to expand the long-lived memory B cell population. Current findings demonstrate that CpG-adjuvanted AVA mediates protection both by stimulating a strong/persistent serum Ab response and by generating a high-affinity long-lived pool of memory B cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18832738      PMCID: PMC2562272          DOI: 10.4049/jimmunol.181.8.5785

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  36 in total

1.  A Toll-like receptor recognizes bacterial DNA.

Authors:  H Hemmi; O Takeuchi; T Kawai; T Kaisho; S Sato; H Sanjo; M Matsumoto; K Hoshino; H Wagner; K Takeda; S Akira
Journal:  Nature       Date:  2000-12-07       Impact factor: 49.962

2.  Search for correlates of protective immunity conferred by anthrax vaccine.

Authors:  S Reuveny; M D White; Y Y Adar; Y Kafri; Z Altboum; Y Gozes; D Kobiler; A Shafferman; B Velan
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

3.  Bioterrorism: a clear and present danger.

Authors:  H C Lane; J L Montagne; A S Fauci
Journal:  Nat Med       Date:  2001-12       Impact factor: 53.440

Review 4.  Anthrax pathogenesis and host response.

Authors:  P Hanna
Journal:  Curr Top Microbiol Immunol       Date:  1998       Impact factor: 4.291

5.  CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma.

Authors:  D M Klinman; A K Yi; S L Beaucage; J Conover; A M Krieg
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-02       Impact factor: 11.205

6.  CpG oligodeoxynucleotides adsorbed onto polylactide-co-glycolide microparticles improve the immunogenicity and protective activity of the licensed anthrax vaccine.

Authors:  Hang Xie; Ihsan Gursel; Bruce E Ivins; Manmohan Singh; Derek T O'Hagan; Jeffrey B Ulmer; Dennis M Klinman
Journal:  Infect Immun       Date:  2005-02       Impact factor: 3.441

7.  Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine.

Authors:  S F Little; B E Ivins; P F Fellows; M L M Pitt; S L W Norris; G P Andrews
Journal:  Vaccine       Date:  2004-01-02       Impact factor: 3.641

8.  Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques.

Authors:  B E Ivins; M L Pitt; P F Fellows; J W Farchaus; G E Benner; D M Waag; S F Little; G W Anderson; P H Gibbs; A M Friedlander
Journal:  Vaccine       Date:  1998-07       Impact factor: 3.641

9.  The mechanism of antigenic stimulation of primary and secondary clonal precursor cells.

Authors:  N R Klinman
Journal:  J Exp Med       Date:  1972-08-01       Impact factor: 14.307

Review 10.  Recent advances in the development of an improved, human anthrax vaccine.

Authors:  B E Ivins; S L Welkos
Journal:  Eur J Epidemiol       Date:  1988-03       Impact factor: 8.082

View more
  19 in total

1.  Correlation between anthrax lethal toxin neutralizing antibody levels and survival in guinea pigs and nonhuman primates vaccinated with the AV7909 anthrax vaccine candidate.

Authors:  Vladimir Savransky; Jeffry D Shearer; Melicia R Gainey; Daniel C Sanford; Gloria S Sivko; Gregory V Stark; Na Li; Boris Ionin; Michael J Lacy; Mario H Skiadopoulos
Journal:  Vaccine       Date:  2017-07-31       Impact factor: 3.641

Review 2.  Toll-like receptors and B-cell receptors synergize to induce immunoglobulin class-switch DNA recombination: relevance to microbial antibody responses.

Authors:  Egest J Pone; Hong Zan; Jingsong Zhang; Ahmed Al-Qahtani; Zhenming Xu; Paolo Casali
Journal:  Crit Rev Immunol       Date:  2010       Impact factor: 2.214

3.  Antibody responses to crucial functional epitopes as a novel approach to assess immunogenicity of vaccine adjuvants.

Authors:  Sita Awasthi; Lauren M Hook; Gokul Swaminathan; Tina M Cairns; Benjamin Brooks; Jeffrey S Smith; Noah T Ditto; Marian E Gindy; Andrew J Bett; Amy S Espeseth; Gary H Cohen; Harvey M Friedman
Journal:  Vaccine       Date:  2019-05-29       Impact factor: 3.641

4.  Stochastic humoral immunity to Bacillus anthracis protective antigen: identification of anti-peptide IgG correlating with seroconversion to Lethal Toxin neutralization.

Authors:  Eric K Dumas; Melissa L Nguyen; Philip M Cox; Heidi Rodgers; Joanne L Peterson; Judith A James; A Darise Farris
Journal:  Vaccine       Date:  2013-02-13       Impact factor: 3.641

5.  Mucosal priming of newborn mice with S. Typhi Ty21a expressing anthrax protective antigen (PA) followed by parenteral PA-boost induces B and T cell-mediated immunity that protects against infection bypassing maternal antibodies.

Authors:  Karina Ramirez; Yanina Ditamo; James E Galen; Les W J Baillie; Marcela F Pasetti
Journal:  Vaccine       Date:  2010-07-07       Impact factor: 3.641

6.  Immunostimulatory CpG oligonucleotides: Effect on gene expression and utility as vaccine adjuvants.

Authors:  Dennis M Klinman; Sven Klaschik; Koji Tomaru; Hidekazu Shirota; Debra Tross; Hidekazu Ikeuchi
Journal:  Vaccine       Date:  2010-02-23       Impact factor: 3.641

Review 7.  CpG DNA as a vaccine adjuvant.

Authors:  Christian Bode; Gan Zhao; Folkert Steinhagen; Takeshi Kinjo; Dennis M Klinman
Journal:  Expert Rev Vaccines       Date:  2011-04       Impact factor: 5.217

8.  Accelerated wound healing mediated by activation of Toll-like receptor 9.

Authors:  Takashi Sato; Masaki Yamamoto; Takeshi Shimosato; Dennis M Klinman
Journal:  Wound Repair Regen       Date:  2010-10-13       Impact factor: 3.617

9.  Randomized, double-blind, active-controlled study evaluating the safety and immunogenicity of three vaccination schedules and two dose levels of AV7909 vaccine for anthrax post-exposure prophylaxis in healthy adults.

Authors:  Robert J Hopkins; Gurdyal Kalsi; Victor M Montalvo-Lugo; Mona Sharma; Yukun Wu; Derek D Muse; Eric A Sheldon; Frank C Hampel; Laurence Lemiale
Journal:  Vaccine       Date:  2016-03-12       Impact factor: 3.641

Review 10.  Recent progress concerning CpG DNA and its use as a vaccine adjuvant.

Authors:  Hidekazu Shirota; Dennis M Klinman
Journal:  Expert Rev Vaccines       Date:  2013-11-26       Impact factor: 5.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.